Recurrent brain tumor study testing rhenium nano-liposome
Part of Brain & nervous system, Cancer clinical trials.
This early-phase study tests a drug made of tiny fat-like particles carrying rhenium for recurrent (coming back) high-grade glioma. It mainly checks safety and the highest tolerable dose, and it also looks for signs the treatment may slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign consent after understanding risks
- You have a confirmed high-grade glioma (grade 3 or 4) that is coming back after prior standard treatment
- Your scans must show the tumor is in the study treatment area and not widespread to the brain lining
- You should be well enough to do daily activities (ECOG 0–2 and Karnofsky 60+), and have at least 2 months expected survival
- Your recent infections, heart issues, and other major illnesses must be stable enough for safe study treatment
- Your blood counts, liver, and kidney tests must meet limits, and you must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether a radioactive treatment delivered in tiny fat “packets” is safe and tolerable when given again to people whose glioma (brain tumor) came back after a previous similar treatment. It also looks at how well this re-treatment works in carefully selected patients.
This trial tests a new drug called SRN-101 that is given directly into the brain tumor before surgery to remove it. The goal is to see if it is safe and could help people with a brain tumor that has come back after standard treatment.
This trial tests a new oral drug called XRD-0394 given together with radiation therapy for people with high-grade glioma, a type of aggressive brain tumor. The goal is to see if adding this drug makes radiation more effective.
This trial tests a radioactive drug (Rhenium-186) injected directly into the brain tumor to see the highest safe dose for children and young adults with ependymoma or high-grade glioma that has come back or is not responding to standard treatments. It may help shrink the tumor without needing surgery right away.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This study tests a new way to deliver radiation directly to the tumor using tiny beads placed during a procedure. It is for people whose glioblastoma has come back after standard treatments, and it aims to slow or stop tumor growth.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.